Adocia
https://www.adocia.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Adocia
Nanobiotix Firmly Back In Business As J&J Comes Onboard
Cash-strapped Nanobiotix has received a major boost with the news that J&J unit Janssen is paying $60m in upfront fees and R&D funding to license NBTXR3, which has the potential to enhance the efficacy of radiotherapy in multiple tumor types including head and neck cancer.
Deal Watch: Takeda Calls Upon The UK’s F-star Again For Bispecific Candidates
Plus deals involving Sanofi/Adocia, Sirnaomics/EDIRNA, Eisai/DRI Healthcare, Sangamo/Voyager, Liquidia/Pharmosa, Tonix/Upsher-Smith and more.
Finance Watch: Cell And Gene Therapy Firms Raised Nearly $20bn In 2020
Private Company Edition: Venture capital mega-rounds continue a brisk pace with machine learning-based drug discovery firm insitro and gene therapy developer Graphite Bio among recent $100m-plus deals. Also, Argobio raised €50m to fund five start-ups in Europe.
Standing On The Shoulders Of Giants: Could Arecor Enter The Race To Revolutionize Diabetes?
A small Cambridge, UK-based company, which is more at home partnering with the pharma industry than competing with it, is readying its run into the diabetes space with its ultra-rapid acting insulin. Scrip talked to its CEO to about the company’s biggest year yet.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice